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Abstract
Background: The aim of this study was to examine the invasiveness of first trimester trophoblasts according to
the secretion profile of MMP-2 and -9 at different gestational stages, and to test the similarity between primary
trophoblast cell-culture and the JAR choriocarcinoma cell-line.
Methods: First trimester trophoblasts were divided into two groups: 6–8 weeks (early) and 9–12 w (late) of
gestation. The two trophoblast groups and JAR cells were cultured in medium, with various concentrations of
forskolin and Epidermal Growth Factor (EGF). Proteolytic activity was detected by zymography and invasiveness
was assessed by Matrigel invasion assay. Student's T-test was used for statistical analysis.
Results:  In 6–8 w trophoblast, proMMP-2 was only slightly dominant over proMMP-9 (53.2% vs. 46.8%
respectively), whereas in 9–12 w, proMMP-9 was clearly dominant over proMMP-2 (61.7% vs.38.3% respectively).
In JAR cells proMMP-2 was strongly dominant (90.2% vs.9.8% respectively). In JAR cells forskolin significantly
increased proMMP-2 and -9 secretion (128.5% +/- 12 and 183.2% +/- 27.9 of control, respectively). EGF had a
dual effect on JAR cells: at 8 ng/ml both proMMP-2 and -9 were increased (133.5% +/-15 and 223.9% +/- 32.4 of
control, respectively) while at 80 ng/ml both proMMP-2 and -9 were decreased (65.1% +/- 18.3 and 66.6% +/- 37
of control, respectively). Forskolin significantly increased both proMMP-2 and -9 secretion in 6–8 w and 9–12 w
trophoblasts (125.9% +/- 6.3,128.4% +/- 6.4; 169.7% +/- 20.3, 120.3% +/- 4.5 of control, respectively). EGF also
significantly increased both proMMP-2 and -9 secretion in 6–8 w and 9–12 w trophoblasts (141.22% +/- 14.8,
138.8% +/- 10.3; 168.3% +/- 18.2, 117.3 +/- 3.8 of control, respectively). Both forskolin and EGF increased
trophoblast cells invasiveness in all groups. The invasive ability of trophoblast cells, induced by forskolin, was
reduced by MMP-2 antibody in: JAR cells, 6–8 w and 9–12 w trophoblasts. Likewise trophoblast invasion induced
by EGF was reduced by MMP-2 antibody in all groups. However the invasive ability induced by forskolin or EGF
was inhibited by MMP-9 antibody only in trophoblasts from 9–12 w.
Conclusions: First trimester trophoblasts express differential gelatinase secretion profile according to the
gestational week. In JAR and early trophoblasts (6–8 w) MMP-2 is the main gelatinase and the key enzyme in
trophoblast invasion. Thereafter in late first trimester trophoblasts (9–12 w), both MMP-2 and -9 participate in
trophoblast invasion.
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Background
Successful implantation depends on the ability of the
embryo to degrade the basement membrane of the uterine
epithelium and to invade the uterine stroma. Cytotro-
phoblastic cells (CTB) are derived from trophoectodermal
cells of the blastocyst. CTB ensue to become either the vil-
lous cytotrophoblastic cells which will proliferate and dif-
ferentiate by fusion to form the syncytiotrophoblast, or
they will stream out of the syncytiotrophoblast to form
mononuclear multilayered invasive extravillous cytotro-
phoblastic cells. The temporal and spatial regulation of
trophoblast invasion is mediated in an auto-and para-
crinic way by trophoblastic and uterine factors [1]. Several
factors have been studied, including hormones, cytokines
and growth factors [2,3]. Trophoblast invasion is facili-
tated by degradation of the extracellular matrix of the
endometrium/decidua by various proteinases, among
them, the matrix metalloproteinases (MMPs). The tissue
inhibitors of matrix metalloproteinases (TIMPs) inhibit
the activity of the MMPs by binding to the highly con-
served zinc-binding site of active MMP [4]. Successful
implantation and trophoblast invasion are closely linked
to the expression of MMPs, which are able to degrade
basement membranes. The gelatinases (gelatinase A:
MMP-2: 72-kDa and gelatinase B: MMP-9: 92-kDa) which
degrade collagen IV, the main component of the base-
ment membrane, are expressed by trophoblast cells and
are therefore regarded as key enzymes in the invasion
process [5]. Several studies have shown that MMP-2 and
MMP-9 synthesis and activation are required for trophob-
last invasion [1,5-9]. Some studies have found either
MMP-9 [5,7,8], or MMP-2 [9-11] to be more pronounced
during the first stage of trophoblast invasion. However,
the exact changes in protease expression during the first
trimester are still not clear. Xu et al [11] found differential
expression of MMP-2 and -9 in first trimester trophoblast
cells, with MMP-2 being the main gelatinase secreted until
9 w and hereafter MMP-9. In this study, trophoblast cells
from first trimester were therefore divided into two groups
according to their MMP secretion profile. The aim of this
study was to examine the expression and importance of
MMP-2 and -9 in human trophoblast invasion, and to test
the similarity between primary trophoblast cell culture
and the JAR choriocarcinoma cell-line. The JAR cell-line
serves as a widely used model for 1st trimester trophob-
lasts [12-14]. The limited availability of 1st trimester tro-
phoblast tissue often requires the use of such a model, and
therefore a comparison study between JAR cell-line and 1st
trimester trophoblasts is of significant importance to
ensure similarity. This study shows a differential, dynamic
importance of each gelatinase in trophoblast invasion
during the 1st trimester.
Methods
Cell culture
The JAR (Jar, HTB 144) human choriocarcinoma line was
established from a trophoblast tumor of the placenta
(1988 American Type Culture Collection Catalogue). The
JAR cells were a generous gift from Prof. Hochberg A
Department of Biological Chemistry, Hebrew University,
Jerusalem, Israel. JAR cells (1 × 104 cells/well) were cul-
tured in M-199 medium (Beit-Ha'Emek, Israel) contain-
ing 10% Fetal Calf Serum (FCS, Beit-Ha'Emek, Israel) and
penicillin/streptomycin (Beit-Ha'Emek, Israel). Cell cul-
ture was maintained in a humidified atmosphere contain-
ing 5% CO2 at 37°C. After 24 hours of culture to facilitate
cell attachment, the medium was removed, and M-199
medium with 1.5% serum supplemented with antibiotics
was added. The cells were cultured with various concen-
trations of: a) Forskolin 1–100 µM, b) Epidermal Growth
Factor (EGF), 0.8–80 ng/ml (Sigma). Control consisted of
M-199 with 1.5% serum alone. Cells were cultured for an
additional 48 hours, and media were removed for analysis
of MMP secretion and stored at -20°C until use. Cell
count was performed with XTT in order to normalize
MMP secretion to cell number.
Isolation and cultivation of human cytotrophoblast cells
Human trophoblast cells were obtained from legal abor-
tions (6 to 12 weeks of gestational age), with the approval
of the local ethical committee (in compliance with the
Helsinki Declaration) and the consent of the participating
patients. Trophoblast cells were isolated as described pre-
viously in detail elsewhere [8,9,15,16] with modifica-
tions. Briefly, tissues were digested by 0.25% trypsin
(Sigma) and DNase I (Sigma) at 37°C, then trophoblast
cells were separated from blood cells and decidua on a
discontinuous Percoll gradient (Sigma) and immunopuri-
fied with magnetic antibody CD45RB (DAKO, Denmark).
The cells were plated at 1–2 × 105 cells/well in 96-well
plates or in Transwell plates (Corning) with M-199
medium supplemented with 1.5% FCS and 1% penicillin/
streptomycin and kept in 5% CO2 at 37°C. Inducers (10
µM forskolin or 8 ng/ml EGF (chosen as working concen-
trations after a dose-response study in JAR cell-line) were
added to medium, and after 48–72 h media were collected
for analysis of MMP secretion and cell count was per-
formed. This method supplies a 95–98% purity of tro-
phoblastic cells, including all trophoblastic sub-groups.
We verified the purity of trophoblast cells by using immu-
nohistochemistry with specific antibodies to cytokeratin 7
(positive) and vimentin (negative), commonly used for
indication of trophoblast purity [7,8,15]. Figure 1 shows
representative pictures of this analysis.
Cell count assay
Evaluation of cell proliferation was performed with XTT
Reagent kit (XTT, cell proliferation kit, Beit-Ha'Emek,Reproductive Biology and Endocrinology 2004, 2:59 http://www.rbej.com/content/2/1/59
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Israel) according to manufactures protocol. This is based
on the activity of mitochondria enzymes in live cells,
reducing tetrazolium salts, XTT, into colored formazan
compounds, which can be detected colorimetric with a
spectrophotometer at 450 nm (ELISA reader). Dye
absorbance is proportional to the number of cells in each
well.
Substrate-gel-electrophoresis (zymography)
In order to detect proteolytic activity in conditioned
media (CM) collected after 48–72 h culture, substrate-gel-
electrophoresis (Zymography) on gels containing gelatin
as the substrate were used as was described by our previ-
ous manuscript [4]. Briefly, CM, was diluted in sample
buffer (5% sodium dodecyl sulphate (SDS), 20% glycerol
in 0.4 mol/l Tris, pH 6.8 containing 0.02% Bromophenol
Blue without 2-mercaptoethanol) and electrophoresed,
through a 10% polyacrylamid gel containing 0.5% gelatin
(50 mg/ml). Afterwards gels were washed twice in 2.5%
Triton X-100 for 15 min. and incubated for 24 h at 37°C
in 0.2 mol/l NaCl, 5 mmol/l CaCl2, 0.2% Brij 35 and 50
mmol/l Tris, pH 7.5. The buffer was decanted and the gels
stained with Coomassie Blue G in 30% methanol and
10% acetic acid for 10 min at room temperature on a
rotary shaker. Stain was washed out with water until clear
bands were seen. Areas where proteolytic activity
degraded the gelatin were seen as absence of staining.
Identification of each gelatinase band was done in accord-
ance to their molecular weight and commercial standards
(gelatinize A and B, 7 µl; Oncogene Science, Cambridge,
MA, data not shown). These bands (proMMP) were quan-
tified using the BioImaging gel documentation system
(Dinco & Renum, Jerusalem, Israel) endowed with TINA
software (Raytest, Staubenhardt, Germany). MMP secre-
tion was expressed as percent of control.
Matrigel invasion assay
Matrigel invasion assay was prepared in our laboratory
with modifications as described in detail elsewhere
[17,18]. Briefly, diluted 1:10 Matrigel (1 mg/ml) (BD Bio-
sciences, Beit-Ha'Emek, Israel) in serum free cell culture
media was added to upper chamber of 24-well transwell
plate, and incubated at 37°C 3–4 h for gelling. JAR Cells
were harvested from tissue culture flasks by Trypsin/
EDTA, washed and resuspended in 1.5% FCS in M-199
medium and added to upper wells at a density of 105 cells/
well in 200 µl medium, while 500 µl medium was added
to lower well. 1st trimester trophoblast were cultured in
upper wells at a density of 2 × 105 cells/well in 100 µl
medium. The same density of cells, in the absence or pres-
ence of activators, was seeded in a well without transwell
and counted at time of the invasion assay, as reference of
total cells. Preliminary studies found no significant
matrigel-mediated changes in multiplication rates
between 6–8 w and 9–12 w trophoblasts, whether seeded
on matrigel or at plastic bottom of well (data not shown).
Activators (10 µM Forskolin or 8 ng/ml EGF) and inhibit-
ing MMP-2 or MMP-9 antibodies (Oncogene Cat. IM33L,
Cat. IM09L; concentration as recommended by manufac-
ture) were added to medium in upper and lower wells.
Plates were incubated at 37°C for 36–48 hours, and then
non-invaded cells on top of the transwell were scraped off
with a cotton swab. The amount of invaded cells in the
lower well as a percent of total seeded cells was evaluated
Representative immunohistochemical analysis of isolated placental cells (6–8 w) after 24 h in culture Figure 1
Representative immunohistochemical analysis of isolated placental cells (6–8 w) after 24 h in culture. (A) Cells stain positive for 
anti-human cytokeratin 7 (1:100, Biogenics). (B) Cells stain negative for anti-human vimentin (1:200, Zymed). Magnification: 
×100.Reproductive Biology and Endocrinology 2004, 2:59 http://www.rbej.com/content/2/1/59
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with XTT Reagent kit. The percent of invasion was calcu-
lated as:
Invasion was expressed as Invasion Index (Percent of
control).
Statistical methods
Results are expressed as mean ± SEM of 5–10 independent
experiments, each treatment performed in duplicates. Sta-
tistical analysis was performed using the SPSS statistical
software. Student's t-test and "one way analysis of vari-
ance" (ANOVA) were used when appropriate. P < 0.05
was considered significant.
Immunohistochemistry
Immunohistochemistry was performed as previously
described [19] using the Histostain-Plus kit (Zymed labo-
ratories Inc., USA). Briefly, cultured cells were fixed with
cytospray for 20 min and quenched with 3% hydrogen
peroxidase in methanol to eliminate endogenous peroxi-
dase activity. The slides were washed, blocked and incu-
bated at room temperature with primary antibodies
(mouse anti-human cytokeratin-7 (1:100, clone OVTL12/
30, Biogenics) and mouse anti-human vimentin (1:200,
clone V9, Zymed laboratories Inc., USA). Secondary anti-
body used: Histostain-Plus broad-spectrum biotinolated
second antibody (Zymed laboratories Inc., USA). Slides
were then developed with a substrate-chromagen solution
of aminoethyl carbazole (Zymed laboratories Inc., USA).
Results
Relative secretion profile of proMMP-2 and proMMP-9 in 
6–8 W, 9–12 W trophoblasts and in JAR cells without 
treatment
JAR cells (1 × 104 cells/well), 1st trimester trophoblast cells
6–8 w and 9–12 w (1–2 × 105 cells/well) were incubated
for 48 hours, then media collected and gelatinase secre-
tion analyzed by zymography. Figure 2 summarizes the
results. In 6–8 w trophoblast, proMMP-2 secretion was
only slightly dominant (statistically not significant) com-
pared to proMMP-9, 53.2% vs. 46.8% respectively (SEM ±
4.3). In 9–12 w trophoblasts the picture was different,
with proMMP-9 being dominant (P < 0.05) over
proMMP-2, 61.7% vs.38.3% respectively (SEM ± 4.6). In
JAR cells proMMP-2 was dominant (P < 0.05), whereas
proMMP-9 only had a small contribution to the gelatinase
secretion, 90.2% vs.9.8% respectively (SEM ± 1.4).
Dose-dependent effect of forskolin and EGF on the 
proMMP-2 and -9 secretion by JAR cells
JAR cells (1 × 104 cells/well) were incubated 48 hours in
the absence or presence of forskolin (1 µM, 10 µM or 100
µM) or EGF (0.8 ng/ml, 8 ng/ml or 80 ng/ml) and media
was analyzed by zymography for gelatinase secretion. Fig
3 summarizes the results. 10 µM forskolin significantly
enhanced secretion of proMMP-2 compared to control
(128.5% ± 12.0, P < 0.05). Forskolin (1 µM and 10 µM)
significantly enhanced proMMP-9 secretion compared to
control (131.3% ± 11.1, and 183.2% ± 27.9, P < 0.05,
respectively) (Fig. 3A). 8 ng/ml EGF significantly
enhanced secretion of proMMP-2 (133.5% ± 15.0, P <
0.05) and of proMMP-9 (223.9% ± 30.4, P < 0.05) com-
pared to control. 80 ng/ml EGF, on the contrary,
decreased proMMP-2 and proMMP-9 secretion compared
to control (65.1% ± 18.3, and 66.6% ± 3.7, P < 0.05) (Fig.
3B).
Effect of forskolin on proMMP-2 and proMMP-9 secretion 
by JAR cells, 1st trimester trophoblast cells 6–8 w and 9–12 
w of gestation
JAR cells (1 × 104 cells/well), 1st trimester trophoblast cells
6–8 w and 9–12 w (1–2 × 105 cells/well) were incubated
for 48 hours in the absence or presence of forskolin 10
µM. Figure 4A shows representative zymography gels. Fig-
ure 4B and 4C summarizes the results. Gelatinase secre-
tion was enhanced by forskolin in all cell groups:
Forskolin significantly increased proMMP-2 secretion in
JAR cells (144.3% ± 8.8, P < 0.05), in 6–8 w trophoblast
(125.9% ± 6.3, P < 0.05) and in 9–12 w trophoblast
(169.7% ± 20.3, P < 0.05) as compared to control (Fig.
4B). Forskolin also significantly increased proMMP-9
secretion in JAR cells (226.6% ± 50.7, P < 0.05), in 6–8 w
trophoblast (128.4% ± 6.4, P < 0.05), and in 9–12 w tro-
phoblast (120.3% ± 4.5, P < 0.05) as compared to control
(Fig. 4C).
Effect of EGF on proMMP-2 and proMMP-9 secretion by 
JAR cells, 1st trimester trophoblast cells 6–8 w and 9–12 w 
of gestation
JAR cells (1 × 104 cells/well), 1st trimester trophoblast cells
6–8 w and 9–12 w (1–2 × 105 cells/well) were incubated
for 48 hours in the absence or presence of EGF 8 ng/ml.
Figure 5A shows representative zymography gels. Figure
5B and 5C summarizes the results. EGF significantly
increased proMMP-2 secretion in JAR cells (130.4% ±
13.1, p < 0.05), in 6–8 w trophoblast (141.22% ± 14.8, P
< 0.05) and also in 9–12 w trophoblast (168.3% ± 18.2, P
< 0.05) as compared to control (Fig. 5B). EGF significantly
increased proMMP-9 secretion in JAR cells (187.8% ±
27.3, P < 0.05), in 6–8 w trophoblast (138.8% ± 10.3, P <
0.005), and in 9–12 w trophoblast (117.3% ± 3.8, P <
0.05) as compared to control (Fig. 5C).
Absorbance of invaded cells x 100
Aborbance of seeded cells
= = Invasion index (%)Reproductive Biology and Endocrinology 2004, 2:59 http://www.rbej.com/content/2/1/59
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Effect of forskolin on cell invasion properties in JAR cells, 
1st trimester trophoblast cells 6–8 w and 9–12 w of 
gestation
JAR cells (105 cells/well), 1st trimester trophoblast cells 6–
8 w and 9–12 w (2 × 105 cells/well) were incubated for
36–48 hours in the absence or presence of forskolin 10
µM on top of Transwell wells containing a transwell mem-
brane coated with matrigel. Forskolin (10 µM) signifi-
cantly enhanced trophoblast invasion in all cell groups.
Forskolin increased cell invasion in JAR cells (110.6% ±
3.4, P < 0.05) (Fig. 6A), in 6–8 w 1st trimester trophoblast
(189.7% ± 14.2, P < 0.05) (Fig. 6B) and in 9–12 w
(302.4% ± 56.0, P < 0.05) as compared to control (Fig.
6C). The addition of inhibitory MMP-2 antibody signifi-
cantly decreased invasion of control cells of JAR cells
(86.5% ± 3.6, P < 0.05) and of 6–8 w (73.8 ± 10.6, P <
0.05) but did not affect 9–12 w trophoblasts. In forskolin-
induced cells the presence of inhibitory MMP-2 antibody
caused a significant decrease in invasion of JAR cells com-
pared with induced cells alone (96.6% ± 1.5 versus
110.6% ± 3.4, respectively P < 0.05), of 6–8 w trophob-
lasts compared with induced cells alone (114.1% ± 24.6
versus 189.7% ± 14.2, respectively, P < 0.05) and of 9–12
w trophoblasts compared with induced cells alone
(188.8% ± 18.4 versus 302.4% ± 56.0, respectively, P <
0.05) (Figure. 6A,6B and 6C)
The addition of inhibitory MMP-9 antibody surprisingly
increased invasion of control cells of 6–8 w and 9–12 w
trophoblast (132.0 ± 8.3 and 134.9 ± 15.2, respectively, P
< 0.05) as compared to control, and only in 9–12 w for-
skolin-induced cells caused a significant decreased inva-
sion compared with induced cells alone (201.5% ± 6.3
versus 302.4% ± 56.0, respectively, P < 0.05). ANOVA
post test confirmed the t test results (Fig. 6A,6B and 6C).
Effect of EGF on cell invasion properties in JAR cells, 1st 
trimester trophoblast cells 6–8 w and 9–12 w of gestation
JAR cells (105 cells/well), 1st trimester trophoblast cells 6–
8 w and 9–12 w (2 × 105 cells/well) were incubated for
(A) Representative secretion pattern of proMMP-2 (72 kD) and proMMP-9 (92 kD) in 6–8 w, 9–12 w trophoblasts and in JAR  cells without treatment as examined with zymography Figure 2
(A) Representative secretion pattern of proMMP-2 (72 kD) and proMMP-9 (92 kD) in 6–8 w, 9–12 w trophoblasts and in JAR 
cells without treatment as examined with zymography. (B) Bar graph describing the relative percentage of gelatinases secre-
tion, representing mean ± SEM from 5 independent experiments. Black bars represents proMMP-2 and white bars represent 
proMMP-9, *P < 0.05.Reproductive Biology and Endocrinology 2004, 2:59 http://www.rbej.com/content/2/1/59
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36–48 hours in the absence or presence of EGF 8 ng/ml on
top of Transwell wells containing a transwell membrane
coated with matrigel. The results of EGF resembled those
of forskolin. EGF enhanced trophoblast invasion in all
cell groups. EGF increased cell invasion in JAR cells
(112.6% ± 2.9, P < 0.05) (Fig. 7A), in 6–8 w 1st trimester
trophoblast (157.9% ± 10.4, P < 0.05) (Fig. 7B) and in 9–
12 w (192.4% ± 10.5, P < 0.05) compared to control (Fig.
7C). In EGF-induced cells the presence of inhibitory
MMP-2 antibody caused a significant decrease in invasion
of JAR cells (100.2% ± 0.8 versus 112.6 ± 2.9, P < 0.05), of
6–8 w trophoblasts (129.7% ± 8.0 versus 157.9 ± 10.4, P
< 0.05) and of 9–12 w trophoblasts (161.1% ± 22.0 versus
192.4 ± 10.5, P < 0.05) compared with induced cells alone
(Figure. 7A,7B and 7C).
The addition of inhibitory MMP-9 antibody affected 9–12
w EGF–induced cells and caused a significant decreased
invasion compared with induced cells alone (169.7% ±
18.1 versus 192.4 ± 10.5, respectively, P < 0.05), ANOVA
post test confirmed the t test results (Figure. 7A,7B and
7C).
Dose-dependent effect of Forskolin and EGF on gelatinase secretion in JAR cells Figure 3
Dose-dependent effect of Forskolin and EGF on gelatinase secretion in JAR cells. JAR cell (1 × 104/well) were incubated 48 
hours with or without Forskolin (1 µM, 10 µM or 100 µM) or EGF (0.8 ng/ml, 8 ng/ml or 80 ng/ml) and media collected for 
measurement of Gelatinase secretion. (A) Bar graph, representing mean ± SEM of 10 independent experiments, of cells 
treated with forskolin. (B) Bar graph, representing mean ± SEM of 10 independent experiments, of cells treated with EGF. 
Black bars represent proMMP-2 and gray bars represent proMMP-9. *P < 0.05 vs. control.Reproductive Biology and Endocrinology 2004, 2:59 http://www.rbej.com/content/2/1/59
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The inhibitory affect of MMP-2/-9 antibody on control
cells was described in the previous section.
Discussion
Trophoblastic invasion of the endometrium is highly reg-
ulated by interrelated reactions between invasion-pro-
moting factors, such as cytokines, growth factors, MMP-2
and MMP-9, and invasion-inhibiting factors such as
TIMPs.
In the current study, the secretion and activity of MMP-2
and MMP-9 in human cytotrophoblastic cells from
different weeks of gestation was measured and compared
with a choriocarcinoma cell-line.
A differential secretion profile of proMMP-2 and -9 was
found between 6–8 w and 9–12 w as expressed by a shift
in the relative proportion of each gelatinase. Elevated
proMMP-9 secretion in 9–12 w was observed, compared
with both 6–8 w and JAR cells. These results are consistent
with those of Xu et al [11], who found MMP-2 production
to be dominant between 6–8 weeks of gestation and then
declining, whereas MMP-9 production significantly
increased from 8 to 11 weeks, with a shift of dominant
Secretion of proMMP-2 and proMMP-9 after 48 hours incubation of JAR cells, 1st trimester trophoblast cells 6–8 week or 1st  trimester trophoblast cells 9–12 week in medium in absence or presence of 10 µM Forskolin Figure 4
Secretion of proMMP-2 and proMMP-9 after 48 hours incubation of JAR cells, 1st trimester trophoblast cells 6–8 week or 1st 
trimester trophoblast cells 9–12 week in medium in absence or presence of 10 µM Forskolin. (A) Representative zymography 
gels. (B) Bar graph, representing mean ± SEM from 10 independent experiments detecting proMMP-2 (72 kD). (C) Bar graph, 
representing mean ± SEM from 10 independent experiments detecting proMMP-9 (92 kD). White bars represent control 
medium of cells without treatment. Black bars represent medium from cells with forskolin treatment. *P < 0.05 vs. control.
Figure 4Reproductive Biology and Endocrinology 2004, 2:59 http://www.rbej.com/content/2/1/59
Page 8 of 13
(page number not for citation purposes)
gelatinase from MMP-2 to MMP-9 from 9 week of
gestation. MMP-2 is predominant in human preimplanta-
tion embryos [20,21], whereas MMP-9 is dominant in the
third trimester [6]. Niu et al [22] reported a dominance of
MMP-2 secretion over MMP-9 from 1st trimester villous
tissue, and a dramatically decrease in MMP-2 levels in the
second trimester. These results support our findings of a
dynamic gelatinase secretion profile during the 1st trimes-
ter.
In our study, MMP secretion was induced by two separate
signal pathways: PKA and PTK. Several factors with impor-
tance in embryo implantation act via the cAMP-protein
kinase A (PKA) signal transduction pathway, including
human chorion gonadotropin (hCG), the primary signal
of an implanting pregnancy [23]. Forskolin is a
prototypical stimulator of the cAMP pathway by direct
activation of adenylate cyclase [24].
In this study, forskolin was found to significantly enhance
proMMP-2 secretion in JAR choriocarcinoma cell-line, 6–
8 w and 9–12 w trophoblasts. Forskolin also enhanced
proMMP-9 secretion, in choriocarcinoma cells and in 1st
trimester trophoblast (from both groups). This indicates
that forskolin might influence trophoblast cells invasive-
ness by enhancing the secretion of gelatinases.
Secretion of proMMP-2 and proMMP-9 after 48 hours incubation of JAR cells, 1st trimester trophoblast cells 6–8 week or 1st  trimester trophoblast cells 9–12 week in medium in absence or presence of 8 ng/ml EGF Figure 5
Secretion of proMMP-2 and proMMP-9 after 48 hours incubation of JAR cells, 1st trimester trophoblast cells 6–8 week or 1st 
trimester trophoblast cells 9–12 week in medium in absence or presence of 8 ng/ml EGF. (A) Representative zymography gels. 
(B) Bar graph, representing mean ± SEM from 10 independent experiments detecting proMMP-2 (72 kD). (C) Bar graph, rep-
resenting mean ± SEM from 10 independent experiments detecting proMMP-9 (92 kD). White bars represent control medium 
of cells without treatment, black bars represent medium from cells with EGF treatment. *P < 0.05 vs. control.Reproductive Biology and Endocrinology 2004, 2:59 http://www.rbej.com/content/2/1/59
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Zymography measures all forms of MMP (active and inac-
tive) and therefore does not reliably represent the true
physiological activity, which is influenced by the presence
of MMP inhibitors and activators. In order to examine the
role of the gelatinases in the implantation process, we
examined cell invasion after PKA stimulation in JAR cells,
6–8 and 9–12 w trophoblasts. Our results showed a signif-
icant increase in invasive ability in JAR cells and in early
Cell invasion ability of JAR cells, 1st trimester trophoblast cells 6–8 week or 1st trimester trophoblast cells 9–12 week tested  with Transwell Invasion Assay Figure 6
Cell invasion ability of JAR cells, 1st trimester trophoblast cells 6–8 week or 1st trimester trophoblast cells 9–12 week tested 
with Transwell Invasion Assay. (A) represents JAR cells, (B) 1st trimester trophoblast cells 6–8 week and (C) 1st trimester tro-
phoblast cells 9–12 week. Cells were treated with 10 µM Forskolin and incubated 36 hours on Matrigel coated membrane, 
with or without MMP-2 or MMP-9 inhibitory antibodies. Cells that invaded the membrane to lower well were counted with 
XTT. Results represent mean ± SEM from 10 independent experiments. Black bars represent control (cells without treatment 
or cells treated with Forskolin) with no antibodies. Gray bars represent cells (without treatment or treated with Forskolin) 
with addition of MMP-2 inhibitory antibody. White bars represent cells (without treatment or treated with Forskolin) with 
addition of MMP-9 inhibitory antibody. ANOVA for all groups results in p < 0.05, post test confirmed the t test results. *P < 
0.05
ure 6Reproductive Biology and Endocrinology 2004, 2:59 http://www.rbej.com/content/2/1/59
Page 10 of 13
(page number not for citation purposes)
and late 1st trimester trophoblasts, after stimulation with
forskolin. In order to detect the contribution of each gela-
tinase to this invasive process, inhibitory antibodies to
MMP-2 and MMP-9 were added to cell culture and cell
invasive ability examined. MMP-2 inhibitory antibody
caused a significant decrease in cell invasion in JAR cells,
6–8 w and 9–12 w trophoblasts treated with forskolin,
whereas MMP-9 inhibitory antibody only caused a
decrease in 9–12 w trophoblasts. This indicates, that most
probably MMP-2 and not MMP-9 is the key-enzyme in the
invasion process of JAR cells and early 1st trimester tro-
phoblasts stimulated by forskolin, whereas MMP-9
Cell invasion ability of JAR cells, 1st trimester trophoblast cells 6–8 week or 1st trimester trophoblast cells 9–12 week tested  with Transwell Invasion Assay Figure 7
Cell invasion ability of JAR cells, 1st trimester trophoblast cells 6–8 week or 1st trimester trophoblast cells 9–12 week tested 
with Transwell Invasion Assay. (A) represents JAR cells, (B) 1st trimester trophoblast cells 6–8 week and (C) 1st trimester tro-
phoblast cells 9–12 week. Cells were treated with 8 ng/ml EGF and incubated 36 hours on Matrigel coated membrane, with or 
without MMP-2 or MMP-9 inhibitory antibodies. Cells that invaded the membrane to lower well were counted with XTT. 
Results represent mean +SEM from 10 independent experiments. Black bars represent control (cells without treatment or 
cells treated with EGF) with no antibodies. Gray bars represent cells (without treatment or EGF treated) with addition of 
MMP-2 inhibitory antibody. White bars represent cells (without treatment or EGF treated) with addition of MMP-9 inhibitory 
antibody. ANOVA for all groups results in p < 0.05, post test confirmed the t test results. * P < 0.05.
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together with MMP-2 plays a role in late 1st trimester tro-
phoblasts. Only a few published data describe the rela-
tionship between forskolin and trophoblast invasion.
Human chorionic gonadotropin acts via cAMP, and is
considered a sign of differentiation of trophoblasts to
syncytiotrophoblast. The hCG receptor was shown to be
expressed on invasive trophoblast and in choriocarci-
noma cells, and hCG was found to increase in vitro inva-
sion and migration of a trophoblastic cell line, an effect
that was also mimicked by forskolin [23]. Several studies
demonstrated a positive correlation between hCG level
and successful implantation [25] or inappropriate
implantation/ invasion associated with the development
of preeclampsia [24] or gestational trophoblastic tumors
[27]. To the best of our knowledge, our study is the first to
report the effect of forskolin on MMPs in first trimester
trophoblastic cells. In addition, this study also distin-
guishes between the contributions of each of the gelati-
nases to the invasive capacity enhanced by forskolin in
trophoblastic cells.
Epidermal Growth factor (EGF) plays a major role in pla-
cental implantation, growth and differentiation and is
regarded a paracrinic factor modifying the implantation
process. EGF acts on trophoblasts via a specific receptor
(EGFR) from the tyrosine kinase receptor family [28]. EGF
is secreted from the endometrium during the implanta-
tion window, in which the embryo also expresses EGFR
[29], and expressed in placenta from 1st throughout third
trimester [30]
In this study EGF stimulated secretion of proMMP-2 in
JAR cells, 6–8 w and 9–12 w trophoblasts and also
enhanced the secretion of proMMP-9 in JAR, in 6–8 w tro-
phoblasts and in 9–12 w trophoblasts. Our results
therefore indicate, that MMP-2 and MMP-9 secretion by
trophoblastic cells may be stimulated through the PTK
pathways during the first trimester. We noted that EGF at
a high concentration (80 ng/ml), in contrast, decreased
proMMP-2 and -9 secretion in JAR cells. This result corre-
sponds with previous published data regarding a dual,
concentration dependent effect of EGF on cell functions
[31,32].
In order to examine the role of the gelatinases in the
implantation process, we examined cell invasion after
PTK stimulation in JAR cells, 6–8 and 9–12 w trophob-
lasts. Our results showed a significant increase in invasion
ability in JAR cells and in early and late 1st trimester tro-
phoblasts, after stimulation with EGF. In EGF-stimulated
JAR cells and in 6–8 w and 9–12 w trophoblasts inhibitory
MMP-2 antibody decreased cell invasion, whereas
inhibitory MMP-9 antibody caused a significant decrease
in invasion only in 9–12 w trophoblasts. We thereby
showed, that in EGF stimulated cells as well, MMP-2 is the
key-enzyme in the invasion process in vitro in JAR cell and
in early 1st trimester trophoblasts, whereas in late 1st tri-
mester trophoblasts both MMP-2 and MMP-9 have a role.
EGF was found to induce changes in morphology and to
increase invasive capacity of first trimester trophoblasts,
whereas later gestational cytotrophoblasts (2nd trimester),
whose invasive capacity is diminished, are much less
affected [29]. EGF was also found to increase MMP-9
secretion by cytotrophoblasts [33].
In JAR control cells inhibitory, MMP-2 antibody also
decreased invasion, whereas MMP-9 antibody had no
affect, indicating that the basic invasive ability of these
choriocarcinoma cells is mainly due to MMP-2 and not to
MMP-9. Inhibition of MMP-2 in control cells also
decreased invasion in 6–8 w trophoblast, but not in 9–12
w, indicating again the importance of MMP-2 in early (6–
8 w) trophoblast invasiveness. Surprisingly inhibition of
MMP-9 in 6–8 w and 9–12 w trophoblasts without treat-
ment caused an increase in invasion. We speculate that
this may be due to a release of other proteinases, includ-
ing other MMPs, since MMP-9 is known to dimerize
[34,35] All in all we found, that in early 1st trimester
trophoblasts (6–8 w), MMP-2 is the major gelatinase par-
ticipant in cell invasion, whereas in later 1st trimester
trophoblasts (>9 w) both MMP-9 and MMP-2 most prob-
ably participate in cell invasion, however we cannot
exclude the possibility of other MMP family members par-
ticipating in this process. Isaka et al [9] have shown that
invasive ability of early first trimester trophoblast was
inhibited by MMP-2 antibody in a dose dependent man-
ner, thereby suggesting that the invasive ability of tro-
phoblasts may be regulated by the enzyme activity of
gelatinases, especially MMP-2. This study supports ours in
the involvement of MMP-2 in trophoblast cell invasion.
MMP-2 was found to be located in invasive evCTB in 1st
trimester placenta [9,10,36], whereas MMP-9 was located
in the non-invasive vCTB [9]. In contrast, several studies
have found MMP-9 to be the key-enzyme in trophoblast
invasion in vitro [1,5,7]. We speculate, that the main rea-
son for this controversy of results comes from the
dynamic gelatinase expression during the 1st trimester, as
earlier discussed. The choice of pathway for stimulation of
cell invasion may also contribute to a difference in results.
We used stimulation through the PKA and PTK pathways;
whereas other groups used the PKC pathway [7,8]. Vari-
ous stimulators, inducing different signal pathways, are
likely not to affect the same enzymes in an identical man-
ner, and thereby can result in varying dominant enzymes.
We found, that MMP-2 is also the key-enzyme in JAR cell
invasion; therefore JAR cells resemble early 1st trimester
trophoblasts in cell invasive ability and in MMP secretion
profile and differ from late 1st trimester trophoblast in
these parameters.Reproductive Biology and Endocrinology 2004, 2:59 http://www.rbej.com/content/2/1/59
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It has been documented, that JAR-trophoblast cells have
the ability to invade in vivo [37,38]. We chose this cell-
line because it provides a large number of uniform cells
and preserve the ability to differentiate into syncytiotro-
phoblast-like cell in vitro [39,40]. Other studies showed
different compartment in vitro between choriocarcinoma
cell-lines and human first trimester trophoblast in the reg-
ulation of invasion [36,37]. The study of JAR cell invasion
may therefore represent only partly the aspects and mech-
anisms of the in vivo situation of invasion, where many
cell types are involved.
Conclusions
We showed that forskolin and EGF stimulate proMMP-2
and -9 secretion from trophoblasts, and that there is a dif-
ferential, dynamic importance of each gelatinase in tro-
phoblast invasion during 1st trimester. We suggest that
MMP-2 is the key-enzyme in JAR and early 1st trimester
(6–8 w) trophoblast invasion, whereas both MMP-2 and -
9 are important for late (9–12 w) trophoblast invasion.
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